RGD Reference Report - Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer.

Authors: Jung, Y  Jun, Y  Lee, HY  Kim, S  Jung, Y  Keum, J  Lee, YS  Cho, YB  Lee, S  Kim, J 
Citation: Jung Y, etal., Oncotarget. 2015 Sep 22;6(28):25368-80. doi: 10.18632/oncotarget.4681.
RGD ID: 11522474
Pubmed: PMID:26196590   (View Abstract at PubMed)
PMCID: PMC4694837   (View Article at PubMed Central)
DOI: DOI:10.18632/oncotarget.4681   (Journal Full-text)

SLC22A18, solute carrier family 22, member 18, has been proposed to function as a tumor suppressor based on its chromosomal location at 11p15.5, mutations and aberrant splicing in several types of cancer and down-regulation in glioblastoma. In this study, we sought to demonstrate the significance of SLC22A18 as a tumor suppressor in colorectal cancer (CRC) and provide mechanistic bases for its function. We first showed that the expression of SLC22A18 is significantly down-regulated in tumor tissues using matched normal-tumor samples from CRC patients. This finding was also supported by publically accessible data from The Cancer Genome Atlas (TCGA). Functionally, SLC22A18 inhibits colony formation and induces of G2/M arrest consistent with being a tumor suppressor. Interestingly, suppression of KRAS by RNA interference promotes SLC22A18 expression, and expression of SLC22A18 in turn inhibits KRAS(G12D)-mediated anchorage independent growth of NIH3T3 cells indicating a mutual negative interaction. Finally, we evaluated diagnostic and prognostic values of SLC22A18 using clinical and gene expression data from TCGA which revealed a significantly worse long-term prognosis for patients with low level SLC22A18 expression. In sum, we established SLC22A18 as a tumor suppressor in colon epithelial cells and propose that SLC22A18 is potentially a marker of diagnostic and prognostic values.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
SLC22A18Humancolon adenocarcinoma amelioratesIEP mRNA:decreased expression:colorectum (human)RGD 
Slc22a18Ratcolon adenocarcinoma amelioratesISOSLC22A18 (Homo sapiens)mRNA:decreased expression:colorectum (human)RGD 
Slc22a18Mousecolon adenocarcinoma amelioratesISOSLC22A18 (Homo sapiens)mRNA:decreased expression:colorectum (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Slc22a18  (solute carrier family 22, member 18)

Genes (Mus musculus)
Slc22a18  (solute carrier family 22 (organic cation transporter), member 18)

Genes (Homo sapiens)
SLC22A18  (solute carrier family 22 member 18)


Additional Information